Shattuck Labs Finalizes $86.25M Public Offering at Discounted Price
STTK has more than doubled off its 52-week low of $0.712 on light trading volume (0.4× avg).
Summary
Shattuck Labs finalized an $86.25 million public offering of common stock and pre-funded warrants, a highly dilutive event priced at a discount to the current market.
Key Events · Financing and Capital Events · STTK
-
Offering Finalized
Shattuck Labs entered into an underwriting agreement to sell 13,691,876 shares of common stock (including full exercise of underwriters' option) at $4.00 per share and 7,870,624 pre-funded warrants at $3.9999 per warrant. The offering is expected to close on June 11, 2026.
-
Significant Capital Raise
The offering is expected to generate approximately $86.25 million in gross proceeds, providing substantial capital for the company's operations.
-
High Dilution
The capital raise represents about 27% of the company's current market capitalization, indicating significant dilution for existing shareholders.
-
Discounted Pricing
The offering price of $4.00 per share and $3.9999 per pre-funded warrant is at a discount to the current market price of $4.165.
Analysis · STTK · Life Sciences
Shattuck Labs has finalized the terms of its public offering, raising approximately $86.25 million through the sale of common stock and pre-funded warrants. This substantial capital raise, representing about 27% of the company's market capitalization, is highly dilutive for existing shareholders and was priced at a discount to the current market price. While providing significant cash to extend the company's operational runway, the terms reflect the cost of capital for a clinical-stage biotech.
At the time of this filing, STTK was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $319.4M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.